1733 Stock Overview
Researches, develops, manufactures, and sells home care medical devices by using biosensor technology worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Apex Biotechnology Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$32.20 |
| 52 Week High | NT$36.25 |
| 52 Week Low | NT$26.40 |
| Beta | 0.36 |
| 1 Month Change | -4.59% |
| 3 Month Change | 7.15% |
| 1 Year Change | -3.88% |
| 3 Year Change | 13.58% |
| 5 Year Change | 39.39% |
| Change since IPO | 90.18% |
Recent News & Updates
Recent updates
Some May Be Optimistic About Apex Biotechnology's (TWSE:1733) Earnings
Nov 21
Apex Biotechnology (TWSE:1733) Will Be Hoping To Turn Its Returns On Capital Around
Aug 06Apex Biotechnology's (TWSE:1733) Conservative Accounting Might Explain Soft Earnings
Mar 21Apex Biotechnology's (TPE:1733) Returns On Capital Not Reflecting Well On The Business
Apr 17Is Apex Biotechnology (TPE:1733) Using Too Much Debt?
Mar 30Is Apex Biotechnology Corp. (TPE:1733) A Good Fit For Your Dividend Portfolio?
Mar 10Is Apex Biotechnology Corp.'s (TPE:1733) Stock On A Downtrend As A Result Of Its Poor Financials?
Feb 17A Look At Apex Biotechnology's (TPE:1733) Share Price Returns
Jan 27
Returns On Capital At Apex Biotechnology (TPE:1733) Paint An Interesting Picture
Jan 06These 4 Measures Indicate That Apex Biotechnology (TPE:1733) Is Using Debt Safely
Dec 16Is Apex Biotechnology Corp.'s (TPE:1733) 4.5% Dividend Worth Your Time?
Nov 22Shareholder Returns
| 1733 | TW Medical Equipment | TW Market | |
|---|---|---|---|
| 7D | 12.0% | 1.0% | 1.9% |
| 1Y | -3.9% | -18.2% | -5.9% |
Return vs Industry: 1733 exceeded the TW Medical Equipment industry which returned -18.2% over the past year.
Return vs Market: 1733 exceeded the TW Market which returned -5.9% over the past year.
Price Volatility
| 1733 volatility | |
|---|---|
| 1733 Average Weekly Movement | 6.4% |
| Medical Equipment Industry Average Movement | 6.4% |
| Market Average Movement | 7.5% |
| 10% most volatile stocks in TW Market | 10.3% |
| 10% least volatile stocks in TW Market | 4.9% |
Stable Share Price: 1733 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 1733's weekly volatility (6%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | n/a | Thomas Shen | www.apexbio.com |
Apex Biotechnology Corp. researches, develops, manufactures, and sells home care medical devices by using biosensor technology worldwide. The company offers blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1C, and ketone monitoring systems, as well as coagulation and multifunctional self-testing, and hemosmart gold hemoglobin screening systems. It also provides pesticide residue check systems; and care management and tele-health services.
Apex Biotechnology Corp. Fundamentals Summary
| 1733 fundamental statistics | |
|---|---|
| Market cap | NT$3.16b |
| Earnings (TTM) | NT$128.00m |
| Revenue (TTM) | NT$1.85b |
25.1x
P/E Ratio1.7x
P/S RatioIs 1733 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1733 income statement (TTM) | |
|---|---|
| Revenue | NT$1.85b |
| Cost of Revenue | NT$1.33b |
| Gross Profit | NT$521.34m |
| Other Expenses | NT$393.34m |
| Earnings | NT$128.00m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.28 |
| Gross Margin | 28.15% |
| Net Profit Margin | 6.91% |
| Debt/Equity Ratio | 0% |
How did 1733 perform over the long term?
See historical performance and comparisonDividends
3.7%
Current Dividend Yield94%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/18 13:00 |
| End of Day Share Price | 2025/04/18 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Apex Biotechnology Corp. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jiahong Liu | E.Sun Securities Investment Consulting Co. Ltd. |
| Ryan Liu | IBTS Investment Consulting Co., Ltd. |
| Zhennan Lee | Jih Sun Securities Investment Consulting Co., Ltd. |